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One of the most prevalent forms of post-transcritpional
RNA modification is the conversion of adenosine
nucleosides to inosine (A-to-I), mediated by the ADAR
family of enzymes. The functional requirement and
regulatory landscape for the majority of A-to-I editing
events are, at present, uncertain. Recent studies have
identified key in vivo functions of ADAR enzymes,
informing our understanding of the biological
importance of A-to-I editing. Large-scale studies have
revealed how editing is regulated both in cis and in
trans. This review will explore these recent studies and
how they broaden our understanding of the functions
and regulation of ADAR-mediated RNA editing.A-to-I editing is performed by the adenosine de-Introduction
The post-transcriptional modification of RNA is a key
process controlling the output of the genome, shaping
the transcriptional landscape and ultimately cellular and
organismal fate. Many types of RNA regulation have
been identified, from differential splicing and isoform
usage through to disctinct classes of chemical modifica-
tion [1]. There are greater than 100 known distinct mod-
ifications that can occur on and to RNA, highlighting
the higher order regulation that can be layered onto
RNA [2]. Of the modifications described to date, a highly
pervasive and prevalent form is the direct enzymatic de-
amination of adenosine nucleosides in RNA, resulting in
their conversion to inosine, a process termed A-to-I
editing [3–5].
A-to-I editing was initially identified as an activity
causing the unwinding of transfected RNA duplexes in
Xenopus eggs [6, 7]. It was subsequently identified that
this unwinding activity was the result of the covalent
modification of the RNA, and that the activity was* Correspondence: cwalkley@svi.edu.au; jin.billy.li@stanford.edu
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activity was found in a range of species, including mam-
mals. The specific characteristic of this modification was
identified based on the analysis of the sequence differ-
ences between the genomic DNA and mRNA sequences
of the GluA2 glutamate receptor (gene name Gria2)
[10]. In this example, there was a change in transcript
and protein sequence from that predicted by the gen-
omic DNA, with an arginine codon (CGG) in the mRNA
in place of the genomically encoded glutamine codon
(CAG). Inosine is resolved as guanosine upon sequen-
cing and also by the translational machinery, meaning
that A-to-I editing is identified as A-to-G variations in
the sequence traces (either Sanger or RNA-seq) com-
pared with the genomic sequence [10–14].
aminase acting on RNA (ADAR) family of proteins
[15–18]. ADARs catalyze the deamination of adeno-
sine to inosine, through the hydrolytic deamination
of the 6-position of adenosine [19]. Inosine preferen-
tially base pairs with cytidine. The editing of adeno-
sines can result in a decrease or an increase in base
pairing of the dsRNA substrate depending upon the
sequence context. While conceptually the identifica-
tion of an edited adenosine should be relatively
straightforward by comparing the transcript sequence
to the genome, this has not proven to be the case
[20–24]. Several factors need to be considered to
accurately define A-to-I editing: that editing occurs
generally at low frequency (the majority of editing
occurs at less than 20% frequency); that errors can
be introduced by random hexamers used to generate
the samples and by the sequencing technology; and
that paralogs and closely related sequences (includ-
ing SNPs) need to be able to be distinguished so
that the events can be assigned accurately within the
genome [21]. The later issue becomes more relevant
when editing of repeat regions, such as Alu and
retrotransposons, is assessed due to the high level of
sequence similarity present in these regions.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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select few well-studied targets, until the parallel
advances in computational methods and sequencing
approaches that generate significantly greater tran-
scriptome coverage converged to allow the accurate
identification of editing in many different species.
Since the identification of this modification and with
the relatively recent advances in sequencing methods,
the number of known sites that can be subjected to
A-to-I editing has grown exponentially, with current
estimates of up to 100 million possible editing events
in the human genome [25, 26].
Types of editing
Two primary types of A-to-I editing have been defined.
The first is site-selective editing [25, 27–29]. This type
of editing refers to the deamination of a specific adeno-
sine in an RNA [10]. This can occur in isolation with no
editing detected at neighboring adenosines or in short
clustered regions within a given transcript (see [30] for
an example). The efficiency of site-selective editing of a
given base varies widely, from near 100% for the canon-
ical example of Gria2 to less than 0.1%, with the
majority of editing occurring at a frequency of less than
20% when assessed genome-wide [31]. An adenosine
subjected to editing in one tissue or subregion of a tissue
may be differentially edited in other tissues or regions of
the same tissue, suggesting that regulation of editing oc-
curs and that it does not represent an “all or none”
phenomenon [31]. There are many additional examples
of highly specific A-to-I editing events [10, 14, 32–34].
Site-selective editing is best associated with transcript
recoding, where the editing causes a change in the pro-
tein sequence and subsequent function [14]. Despite the
capacity for protein recoding arising from A-to-I editing,
the proportion of editing events that result in this out-
come are a very small minority of those now described
in mammalian genomes, and the degree of conservation
of these is generally low [26, 35]. The consequences of
recoding can vary, from the introduction of silent muta-
tions with no discernable consequence for protein func-
tion through to mutations that alter the function of the
protein dramatically, with the GluA2 Q/R site defining
this latter paradigm [12–14, 32, 33].
The second and distinctive type of A-to-I editing is hyper-
editing [36, 37], which refers to a similar phenomenon as
editing enriched regions (EERs) [38, 39]. Hyper-editing is in-
dicated by the editing of a large or excessive proportion of
adenosines in close proximity to each other within the same
transcript [40–42]. In mammals, this class of editing is
mostly associated with regions of repetitive sequence where
high levels of homology arise from the base pairing of
inverted repeats, resulting in the editing of a high proportion
of adenosines in a short region of several hundred base pairs[36]. This primarily occurs in intronic regions and 3′ UTRs
in the mammalian context. In humans and primates this in-
cludes Alu elements and other types of repetitive regions
[26, 28, 35, 43]. This type of extensive editing has also been
observed in viral sequences, where the viral dsRNA can be
subjected to extensive editing in the infected cell [9, 44–47].
Expansion of RNA editing sites
The initial identification of A-to-I editing sites was
largely based on serendipitous discoveries stemming
from the detailed assessment of a single transcript
[10, 48]. Evidence for hyper-editing first arose from
virology, where it was noted that the dsRNA of cer-
tain types of virus could be heavily modified [9, 49].
Methods were developed, and more recently adapted
for use with high-throughput sequencing, to allow
identification of inosine-containing transcripts. These
approaches rely on either the preferential cleavage of
inosine-containing transcripts by enzymes such as
RNAse T1, or upon the chemical conversion of in-
osine by cyanoethylation, to allow identification of
edited sites [50–52].
Methodologies to systematically map A-to-I editing
have primarily utilized the in silico analysis of expressed
sequence tag databases or, more recently, the analysis of
large RNA-seq datasets [26–28, 31, 35, 43, 53–55]. With
the advent of high-throughput sequencing technologies,
which have enabled base resolution analysis of most of
the genome and the rapid cost per base reductions in
their utilization, the numbers of editing sites catalogued
has dramatically expanded [25, 26, 35, 56]. Targetted
approaches, such as microfluidic multiplex PCR and se-
quencing (mmPCR-seq), allowing the highly accurate
sampling of editing at a significant number of known
editing sites across a range of tissues/samples at low
cost, have added significantly to our ability to profile
editing across tissues of an organism [57]. These ap-
proaches have also made possible the comparison of
editing among species and phyla, providing important
understanding of its prevalence and clues to its function
in different contexts [42, 58]. The analysis of editing
across and within species has been highly informative to
our understanding of the extent and consequences of A-
to-I editing over evolution [56, 59–61]. The inclusion of
genetically modified cells and organisms, such as tissues
from the various ADAR knockout animals and cell lines
with reduced ADAR expression/function, has enabled
the experimental validation of large numbers of the sites
that have been identified computationally in addition to
the discovery of additional sites [40, 41, 62, 63]. These
complementary approaches have provided important
validation of the methods and have been extended to
begin to understand the differential effects and site pref-
erences of the individual ADAR proteins.
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genetic variants (A-to-G transitions on the forward strand,
T-to-C on the reverse strand) present in the RNA-seq data
but absent in the matched whole genome sequence from
the same individual or species [28, 64]. More recently,
methods have evolved and a number of rigorous methods
have been established to identify RNA editing sites,
including those that can use RNA-seq alone rather than a
reference genome [29, 65, 66]. Furthermore, special
techniques have been developed to identify hyper-editing
sites that often escape from the conventional approaches
[36]. This has been necessary due to the excessive
numbers of edited bases in regions of hyper-editing which
can impact on genomic alignment of these regions,
making differentiation of these regions from sequencing
errors of “bad reads” imperative. A historical view of the
development of methods to reliably identify RNA editing
sites is summarized in detail in a recent review (see refer-
ence [26] for a detailed perspective on this topic). Several
databases are publically available to assess and query
RNA-editing sites across species, including RADAR [35],
DARNED [67, 68], and REDIbd/REDItools [69].
ADAR proteins
The numbers and conservation of ADARs varies across
species. Mammals have three proteins: ADAR1 (ADAR),
ADAR2 (ADARB1), and ADAR3 (ADARB2); Drosophila
melanogaster has a single Adar (phenotypically most simi-
lar to mammalian ADAR2 [70, 71]); and Caenorhabditis
elegans has two genes, adr-1 and adr-2 (phenotypically
most similar to ADAR3 and ADAR2, respectively [72]).
Each ADAR has dsRNA binding regions and a highly con-
served carboxy terminal catalytic domain, distantly related
to the bacterial cytidine deaminases [17, 73]. Mammalian
ADAR1 and ADAR2 have demonstrated catalytic activity
and participate in A-to-I editing; in contrast, no editing
activity has been detected with ADAR3 on known sub-
trates and it appears to be catalytically inactive [74, 75].
Unlike ADAR1 and ADAR2, ADAR3 does not appear to
homodimerize and this may be an important contributor
to its lack of activity [17, 74]. Similarly, in C. elegans adr-2
is capable of A-to-I editing while adr-1, akin to mamma-
lian ADAR3, does not display editing activity [72].
The expression of each of the ADARs varies across de-
velopment and tissues in mammals [76]. ADAR1 is widely
expressed throughout the body and is the most highly
expressed ADAR outside the central nervous system
(CNS). A unique feature of ADAR1 is that it can be
expressed as two distinct editing competent isoforms, and
increasing evidence supports that these may have both
overlapping and distinctive functions [18, 30, 77, 78].
ADAR1 is expressed as a consititutive p110 kDa isoform
(ADAR1 p110), which localizes primarily to the nucleus,
and an inducibile ADAR1 p150 isoform [79]. The largerisoform can be induced by activation of the interferon and
innate immune sensing system and localizes to the
cytoplasm [18]. ADAR2 and ADAR3 are most highly
expressed in the brain and CNS, with expression more re-
stricted in other tissues. ADAR2 contributes significantly
to editing in the testis in the mouse [80]. The completion
of detailed body maps and single cell studies of gene ex-
pression will enable a significantly refined understanding
of when and how different ADARs are expressed through-
out the body.
The phenotypes associated with loss of function of
ADARs differ between species. In C. elegans deletion of
adr-1 or adr-2 resulted in defects in chemotaxis [81],
phenotypes that are consistent with a role in neuronal
function. Interestingly, the chemotaxis defect could be
rescued by concurrent deletion of components of the
RNAi pathway, including rde-1 and rde-4, implicating an
interaction between RNA editing and RNAi pathways
[82]. Very recently, the chemotactic defect in adr-2-defi-
cient C. elegans has been determined to be an editing-
dependent effect [83]. The normal expression of the
mRNA of clec-41, a predicted C-type lectin protein, was
dependent upon editing by ADR-2. In ADR-2-deficient
cells, the expression of clec-41 was significantly reduced.
When clec-41 expression was restored in adr-2-deficient
neural cells, the chemotactic defect could be rescued,
providing direct evidence that neuronal/chemotactic
phenotypes of adr-2 mutants can be attributed to altered
gene expression of an edited transcript [83].
Deletion of the single ADAR in Drosophila resulted in
behavioral and locomotion abnormalities with brain le-
sions upon aging [70, 84, 85]. More recently, hypomorphic
alleles have been established in Drosophila which have de-
fects in sleep patterns [86], with evidence for a conserved
disruption of circadian rhythm in Adar2–/–- mice [87]. In
both C. elegans and Drosophila, the germline deletion of
ADARs is compatibile with life and the mutants are viable
but phenotypic [88]. Phylogenetic analysis demonstrated
that mammalian ADAR2 could rescue Drosophila Adar
null mutants, but that mammalian ADAR1 could not [71].
This result, coupled with evolutionary analysis, suggested
that ADAR1 and ADAR2 evolved separately and have
conserved, but specialized, functions. Analysis of mamma-
lian mutant models has now confirmed this.
In mice, deletion of Adar2 resulted in the fully penetrant
development of postnatal seizures that ultimately result in
death by 20–25 days of age [13]. This phenotype was res-
cued by the substitution of a single adenine to guanine in
the Q/R position of the Gria2 gene, mimicking constitu-
tive editing at this site [11, 13]. The rescued Adar2–/–
Gria2R/R animals have a normal lifespan, are fertile, but
have some subtle phenotypes that were revealed by broad-
based phenotyping [89]. This elegant model of rescue of
lethality by a single A-to-I site substitution within a single
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ADAR-mediated editing resulting in protein recoding as
an essential consequence of A-to-I editing. Retrospectively,
this result was also confounding as it suggested that editing
of a large range of sites that have been subsequently defined
was of limited biological relevance. Alternatively, it hinted
that most editing may be required for “fine tuning” rather
than being essential for homeostasis in mammals, and so
may require specific contexts or settings for phenotypes to
be revealed. However, as we now appreciate, the levels of
redundancy and overlap of editing substrates between
ADAR1 and ADAR2 are important considerations when
interpreting the in vivo results.
In contrast to the Adar2–/–- phenotype, the deletion of
Adar1 (Adar1–/–, both p110 and p150 isoforms [30, 90]),
the deletion of the p150 isoform specifically (Adar1p150–/–-
[77]), or the specific inactivation of the editing activity/cata-
lytic domain (Adar1E861A/E861A, both p110 and p150 are
editing deficient [41]) resulted in embryonic lethality
between E11.5 and E13.5. These animals are charac-
terized by a failure in fetal hematopoiesis and liver
disintegration, marked by high levels of cell death.
Subsequent studies identified the profound deregula-
tion of transcripts related to the innate immune sens-
ing (interferon) response upon deletion or mutation
of ADAR1 [91]. Using genetic intercrosses of the
Adar1 mutants it has been identified by several
groups including our own that a key in vivo function
of ADAR1 is to modify endogenous RNA, via editing,
to prevent activation of the cytosolic dsRNA sensing
pathway centred on MDA5 and its downstream ef-
fector MAVS (Table 1) [41, 78, 92]. A number of gen-
etic pathways have been tested by crossing to the
Adar1 mutants and assessing rescue of viability. Of the
pathways tested in vivo, to date the only significant rescue
has been achieved with the deletion of MDA5 and MAVS
[41, 78, 92]. This function is unique to ADAR1, and is not
shared by other mammalian ADARs. It was recently
reported in human cell lines that deletion of RNaseL
could rescue the viability of ADAR1–/– cell lines, in a
comparable manner to deletion of MAVS [93]. It is
not presently clear whether the requirement for RNa-
seL is downstream of MDA5/MAVS signaling or can
be initiated independently of this axis and whether
the effect is physiologically relevant in vivo.
A question that has not been definitively resolved is
the extent to which the phenotypes seen in the different
mutant mouse models are due to editing-dependent or
editing-independent functions. This is reasonably clear
for the Adar2–/– animals, with the profound rescue of
the phenotype in these mice by the Gria2R/R allele dem-
onstrating that the physiologically most important func-
tion of ADAR2 is A-to-I editing. The Adar2–/–Gria2R/R
animals do have additional subtle phenotypes that wererevealed after a comprehensive phenotypic analysis and
testing suggesting that there are specific requirements
for ADAR2 outside of Gria2 editing; however, whether
these reflect the lack of editing of specific substrates or
editing-independent functions is not clear [89]. In the
case of ADAR1, a number of editing-independent func-
tions have been proposed and phenotypes observed in
rescued mice that were interpreted as independent of
the editing activity of ADAR1. These range from roles in
miRNA biogenesis [94–100], affecting mRNA stability
[100–102], alternative 3′ UTR usage [97], and altering
RNA splicing [103, 104] and the rates and efficiency of
translation [105]. In vivo, the small numbers of Adar1–/–
Mavs–/– and Adar1p150–/–Mavs–/– rescued mice that
survived past 10 days of age had developmental defects
in the kidney, small intestine, and lymph node and a fail-
ure of B lymphopoiesis [78]. In contrast to these re-
ported roles for editing-independent activities of
ADAR1, we found that an Adar1 editing-deficient allele
(Adar1E861A) demonstrated highly comparable pheno-
types in both a germline-deficient or acute adult somatic
deletion model to ADAR1 null alleles [40, 41, 106]. That
the specific absence of editing, with a protein still being
expressed, and the complete absence of the protein are
so similar argues strongly that there are limited add-
itional in vivo functions for the protein beyond editing.
These genetic results do not exclude context-specific
functions of ADAR1 independent of editing that were ei-
ther not assessed or not active in the cell types assessed
(primarily hematopoietic cells). At an organismal level
A-to-I editing is the most essential function of ADAR1
and this function is required to prevent inappropriate
activation of the innate immune system by endogenous
RNA species.
No editing activity has been demonstrated by ADAR3.
The role of mammalian ADAR3 is less clear, but data
are accumulating from both C. elegans and mammalian
models that ADAR3 may act to reduce the availability of
substrates for ADAR1 or ADAR2, resulting in a net
overall inhibitory effect on editing levels [72, 75, 76]. No
phenotypes similar to those identified in the Adar1 and
Adar2 mutants have been reported for Adar3–/– animals
to date. Therefore, it is the combination of expression
patterns of the different ADAR isoforms that can deter-
mine the nature and extent of editing in a given cell and
tissue, with ADAR3 providing a counterpoint to ADAR1
and ADAR2 [76].
These genetics studies have refined our understanding
of the functions of A-to-I editing and of the individual
roles that ADAR isoforms fulfill in vivo: ADAR2 is key
to site-selective editing, especially in the CNS, whereas
ADAR1-mediated editing has an essential role in the
prevention of activation of the cytosolic dsRNA innate
immune sensing system by endogenous RNA (Fig. 1).
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Fig. 1 The roles of ADAR1, ADAR2, and ADAR3. ADAR1 is present in the nucleus (ADAR1 p110) and cytoplasm (ADAR1 p150) and can edit endogenous
RNA. ADAR1 is required to edit endogenous RNA to prevent the activation of the cytosolic pattern recognition receptor MDA5 in the cytosol, leading to
induction of the innate immune/interferon response. ADAR1 can also edit viral dsRNA and participate in the innate immune response as a direct
interferon-stimulated gene (ADAR1 p150 isoform). The absence of ADAR1 or the absence of ADAR1-mediated editing leads to innapropriate activation of
the MDA5–MAVS axis. ADAR2 is essential for site-selective editing and is very highly expressed in the brain and central nervous system. The editing of Gria2
at the Q/R site is ADAR2 specific and is required to recode the transcript to form a functional GluA2 protein and allow survival. ADAR3 competes with
ADAR1 or ADAR2 for binding to dsRNA substrates, which then are protected from editing due to ADAR3 not having deamination activity
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While our appreciation of the numbers and extent of
editing has rapidly expanded, it is less well understood
how this process is physiologically regulated. For ex-
ample, it is established that the same RNA transcript in
different regions of the brain is subjected to variable
levels of editing [28, 31]. Studies have now described A-
to-I editing from very early development in single cells
to the analysis of a specific brain region over a cohort
spanning a large proportion of the lifespan of humans
[107, 108]. Such studies have identified the dynamic
regulation of A-to-I editing, both temporally and devel-
opmentally, indicating a process modulated at multiple
levels.
A key contributor to the difference is the distinct pat-
terns of expression of the ADAR proteins. Our recent
work analysing thousands of human RNA-seq data sets
from the GTEx project revealed that the expression of
ADARs partially, but not fully, accounts for the variation
of RNA editing levels [76]. Different ADARs appear to
play distinct roles. Specifically, ADAR1 and ADAR2 ex-
pression can explain about 20 and 2.8%, respectively, of
the variation in overall editing of repetitive sites. In con-
strast, for non-repetitive protein-coding sites, ADAR1
and ADAR2 expression can explain 6 and 25% of the
variation, respectively. Intriguingly, ADAR3, which is en-
zymatically inactive, negatively affects RNA editing, pos-
sibly by competing with ADAR1 and ADAR2 to bind theediting substrates, a finding consistent with observations
in model organisms [76]. These findings suggested im-
portant roles of ADARs in regulating RNA editing, but
also prompt searches for additional regulators and modi-
fiers of RNA editing to better account for the editing
variation. These include the influence of the structure of
the dsRNA containing the targeted adenosine, the neigh-
boring bases to the editing site and the influence of
other RNA binding proteins or modifers of ADAR func-
tion. Collectively these factors combine to result in the
observed level of editing for a given site.
Cis regulation of A-to-I RNA editing
Both cis and trans effects contribute to the regulation of
RNA editing. Cis regulation refers to the primary RNA
sequence and secondary dsRNA structure as the
substrate for editing. Trans regulation indicates that
trans-acting factors, such as ADARs and other regula-
tors, alter the editing efficiency observed at a given locus
(Fig. 2). We have recently generated two independent
lines of evidence suggesting that RNA editing is mainly
regulated in cis. First, when we compare RNA editing of
conserved sites in multiple tissues from human, primate,
and mouse, the samples are clustered by species types,
rather than by tissue types [76]. This is very similar to
the findings that RNA splicing regulation is also mainly
cis directed [109, 110]. Second, using closely related
Drosophila species, D. melanogaster and D. sechellia,
Fig. 2 Cis versus trans regulation of A-to-I editing. Cis regulation contributes significantly to the efficiency of editing by ADARs. The sequence context and
secondary structure surrounding the adenosine are important in determining the efficiency of editing. The 5′ and 3′ nucleotides adjacent to the adenosine
are important contributors to the editing efficiency. Trans regulation contributes less significantly to the overall editing, and can either enhance editing,
such as occurs with Pin1 phosphorylation of ADAR, or reduce overall editing, as occurs with WWP2 (ubiquitination of ADAR) or AIMP2 (reduces overall
levels of ADAR1)
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sequences from trans regulators by comparing species-
specific editing levels in F1 hybrids and their parents.
We found that cis sequence differences are largely
responsible for editing level differences between these
two Drosophila species, whereas trans regulators are
likely only responsible for subtle changes [111]. These
data prompt us to better understand the underlying
rules of RNA editing cis regulation.
How ADARs target a specific A-to-I RNA editing
site is a long-standing question that is not well ad-
dressed. Both the primary sequence and secondary
structure (i.e., cis-acting regulatory elements) sur-
rounding the editing site guide the preference and
selectivity of ADARs. ADAR has a preferred sequence
motif neighboring the targeted adenosine, in particu-
lar the 5′ and 3′ nearest neighboring positions to the
editing site, with the depletion and enrichment of G
upstream and downstream of the editing site, respect-
ively [50, 112, 113]. Recent analysis of crystal struc-
tures of human ADAR2 deaminase domain bound to
substrate RNA now provide a basis for the nearest
neighbor preference of ADARs [114]. These structures
demonstrated the 5′-neighbor preference for a U or
A, as when this base is a G or C there is a destabiliz-
ing interaction with the backbone of the ADARprotein which reduces, but does not abolish, the
interaction and thus impacts on editing efficiency.
Additionally, adenosines edited in a dsRNA are
affected by mismatches, bulges, and loops both posi-
tively and negatively, implicating complex structural
contributions to editing specificity [112, 115]. While
these specific examples are informative, they prompt
systematic studies to more completely decipher the
cis regulatory code of RNA editing.
We and others recently applied a quantitative trait locus
(QTL) mapping approach to identify genetic variants asso-
ciated with variability in RNA editing [116–118]. With
accurate measurement of RNA editing levels at 789 sites
in 131 D. melanogaster strains, we identified 545 editing
QTLs (edQTLs) associated with differences in RNA
editing [117]. We demonstrated that many edQTLs can
act through changes in the local secondary structure for
edited dsRNAs. Furthermore, we found that edQTLs
located outside of the edited dsRNA duplex are enriched
in secondary structure [117]. While these studies are un-
precedented, future studies are needed to systematically
understand the features of RNA sequence and structure
to enable deciphering of the cis regulatory code of RNA
editing. Consistent with these results, an assessment of
editing across 21 diverse organisms concluded that editing
is enriched in regions of putative double-strandedness and
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ther confirmed the near unique requirement for editing in
cephalopods (octopus/squid), where there is a profoundly
elevated level of A-to-I editing [42, 56, 60].
An additional finding from the analysis of the crys-
tal structures of the human ADAR2 deaminase do-
main bound to an RNA substrate was that differences
between the ADAR proteins themselves may affect
substrate specificity [114]. It was identified that both
ADAR2 and ADAR1 share homology for a previously
unrecognized side chain (R510 in ADAR2) which is
absent in ADAR3. This residue interacts with the
RNA substrate and mutation of the R510 residue in
hADAR2 to either a glutamine or an alanine reduced
the deaminase activity by an order of magnitude [114].
This difference may be an important contributor to the in-
ability of ADAR3 to edit. It was also reported that there
are differences between the RNA-binding loops of ADAR2
and ADAR1. These differences may be important in sub-
strate selection and editing efficiency of a given substrate
by ADAR1 and ADAR2. Therefore, the collective effect of
RNA substrate structure, the sequence context surround-
ing the adenosine, and which ADAR protein binds all con-
tribute to the efficiency of editing at a given adenosine.
Trans regulators and modifiers of ADARs and
editing efficiency
Beyond ADAR editing enzymes themselves only a handful
of proteins have been identified that modulate RNA editing,
despite speculation about the existence of additional trans
regulators involved in the RNA editing machinery. In
Drosophila, the fragile X protein FMR1 biochemically and
genetically interacts with ADAR to influence editing levels
[119], the RNA helicase maleless controls the editing of
one transcript through regulating its splicing [120], and the
transcription factor period is thought to modulate editing
at a small number of sites through an unknown mechanism
[121]. However, these regulators combined explain editing
level regulation at fewer than 1% of known editing sites in
Drosophila, underscoring the need for additional efforts to
identify editing regulators with broader effects.
In mammals, two proteins are known to regulate
ADAR2’s global activity through post-translational modi-
fications. Pin1 promotes editing by binding ADAR2 in a
phosphorylation-dependent manner, while WWP2 de-
creases editing by targeting ADAR2 for ubiquitination
[122]. By taking advange of the large GTEx dataset, we
recently identified AIMP2 as a novel negative regulator
of RNA editing because its expression is negatively cor-
related with overall editing levels across thousands of
samples. Further experimental validation demonstrated
that AIMP2 acts to inhibit RNA editing, at least par-
tially, through lowering the protein level of ADARs [76].
Additionally, a genetic screen in yeast expressingmammalian ADAR2 identified a handful of mammalian
enhancers and suppressors of ADAR2 editing, mostly
RNA binding proteins, which appear to regulate a small
number of sites [123, 124]. There is a clear need for sys-
tematic searches of novel RNA editing regulators in
mammals to better explain the dynamic regulation pat-
terns that have been observed.
ADARs, editing, and disease: what happens when
editing goes awry?
The available data suggest a more pronounced separ-
ation of biological function between ADAR1 and
ADAR2 than was previously expected. Mutations in
ADAR2 have not been reported to be associated with
human disease. In contrast, mutations of ADAR are
associated with the human diseases dyschromatosis
symmetrica hereditaria (DSH) [125, 126] and Aicardi–
Goutières syndrome (AGS) [127–129]. Over 100 het-
erozygous ADAR mutations have been reported in
DSH and are associated with altered pigmentation
(areas of hypo- and hyperpigmentation) on the face
and dorsal aspects of the extremities that first appear
in infancy/early childhood. This condition is not fatal
and the symptoms appear to be largely restricted to
the skin.
More recently, and contrasting with the phenotypes of
DSH, Crow, Rice, and colleagues identified biallelic
ADAR mutations as one of the genetic causes of AGS
[127]. AGS has some clinical features that are similar to
congenital viral infections. AGS patients, including those
with ADAR mutations, develop a severe neurodevelop-
mental disorder characterized by intracranial calcifica-
tions and motor disorders, and have evidence of an
activated innate immune/interferon response (“interfero-
nopathy”) in their peripheral blood, consistent with the
results from murine mutants [130]. Mutations in eight
genes are associated with AGS, with a clustering of
genes involved in cytosolic DNA metabolism (TREX1,
RNASEH2B, RNASEH2C, RNASEH2A, SAMHD1) and
those regulating cytosolic RNA metabolism (ADAR and
IFIH1) [129, 131]. In AGS, unlike DSH, biallelic
mutations of ADAR are seen in affected patients and are
predicted to be significantly more detrimental to the
RNA editing/interacting potential of the mutant pro-
teins. Interestingly, despite the significantly different
numbers of repetitive elements between the species (Alu
repeats are primate restricted), the transcriptional re-
sponse to ADAR1 deficiency is conserved between
mouse and human, as is the specific requirement for
MDA5 in this response [78]. These results, corroborated
by evidence from murine models, demonstrate that sig-
nificant reductions in the activity of ADAR1 are poorly
tolerated in vivo. In contrast to the deleterious conse-
quences of reduced ADAR1 function in human kindreds,
Walkley and Li Genome Biology  (2017) 18:205 Page 9 of 13germline mutations in ADAR2 or ADAR3 have not yet
been clearly described or associated with human disease.
A range of different human diseases are associated with
altered editing and ADAR activity. In these cases, the dir-
ect mutation of the ADAR genes does not cause this asso-
ciation, as is seen in AGS. There is a significant body of
work demonstrating reductions in editing, principally as-
cribed to ADAR2, in a range of neuronal and CNS disor-
ders, including Alzheimer’s disease and amyotrophic
lateral sclerosis [132–136]. In the majority of cases, these
studies have reported reduced editing of specific targets in
these disease settings when compared with normal tissue
or non-affected samples. To date there has not been a
clear association of reduced ADAR1 function with dis-
eases of the CNS, outside of the germline diseases noted
above. This contrasts with the clinical phenotypes of AGS,
when profound changes in the CNS are observed in pa-
tients with biallelic mutation in ADAR.
Our appreciation of the extent and characteristics of A-
to-I editing have rapidly expanded, paralleling the techno-
logical advancements in sequencing methods. This has
been particularly informative in the context of cancer,
where large datasets from diverse human cancers have
been harnessed to identify links between altered A-to-I
editing levels and a range of different cancer types. Initial
reports described changes, generally reductions, of
ADAR2-mediated editing at selected targets in tumors of
the CNS such as glioblastoma and astrocytoma [137, 138].
Recent studies utilizing large RNA-seq datasets from hu-
man cancers have identified a trend of increased overall
editing and ADAR1 expression in cancer types ranging
from leukemias to solid tumors [33, 95, 139–145].
Reasons for the increased ADAR1 expression have been
associated with both copy number gains at chromosome
1, where the ADAR gene resides, and the activation of
interferon/innate immune sensing responses in tumors
leading to an increase in ADAR1 expression. The bio-
logical consequences of increased ADAR1 and an in-
creased level of overall editing in tumors is only beginning
to be explored. In some specific examples, such as in
melanoma, reduced editing efficiency has been proposed to
be important in the pathogenesis of these tumors [146, 147],
although this appears to be less common than increased
expression of ADAR1 and higher overall editing levels. Our
understanding of the consequences of changes in A-to-I edit-
ing on cancer initiation and maintenance, both at the level of
its effect on specific transcripts and also on the global tran-
scriptomome of the cancer cells, is only beginning to be ex-
plored, and how this contributes to tumor evolution requires
further study.
Future directions
Our understanding of the landscape of A-to-I editing
has rapidly expanded over the past decade. The effortsof many investigators have enabled us to catalogue edit-
ing across the transcriptomes of many species. The abil-
ity to identify editing with high confidence at the
genome scale has enabled a better understanding of how
editing contributes to genome diversity in a range of
contexts: evolutionarily, developmentally, and pathogeni-
cally. Paralleling the identification of A-to-I editing
events, studies using genetically modified organisms
have greatly enhanced our understanding of the in vivo
roles and functions of ADARs. These studies have estab-
lished that ADAR1 serves a unique function in the regu-
lation of the innate immune response to self-RNA, while
ADAR2 principally contributes to editing in a more site-
selective manner, and ADAR3 competes with ADAR1/2
for substrates, but does not edit them directly. Further
studies have broadened our understanding of factors
contributing to A-to-I editing efficiency of a given
substrate, principally the cis regulation of RNA sequence
and structure surrounding the edited adenosine and, to
a lesser extent, the trans regulation of ADAR protein
activity/levels by other cellular proteins. At the cellular
level, how altered A-to-I editing, both increased and
decreased, impacts cell fate is only beginning to be
explored. This is particularly relevant in disease
contexts, where evidence has solidified that there is al-
tered activity of ADAR proteins. In inherited disorders
such as AGS the loss/reduction of ADAR1 activity has a
profound impact on normal functioning and is ultim-
ately lethal. In cancer, where elevated ADAR1 expression
and activity have been frequently reported, it remains to
be shown if these reflect a function in driving tumor ini-
tiation and maintenance or reflect the physiological
function of ADAR1, to edit endogenous dsRNA to pre-
vent activation of the innate immune system. Many of
the tools developed to allow our present understanding
of the physiological roles of ADARs can be applied to
understand these pathogenic roles.
Modifications of RNA, outside of A-to-I editing, are
increasingly being defined as key regulators of transcrip-
tional output and more than 100 distinct types of modi-
fications have been identified to date [1, 2]. This raises
many important questions about how these modifica-
tions are co-ordinated and interact with/influence each
other, ultimately impacting the fate of the given RNA
and cell. Such conceptual models have been established
and experimentally defined for the interactions of modif-
cations impacting DNA and chromatin. As an example
of an RNA modification, N(6)-methyladenosine (m6A) is
the most frequent internal modification of mRNA [148].
There are many parallels between the roles identified for
m6A and those of A-to-I editing, including roles in the
viral life cycle [149, 150] and in the regulation of cell fate
determination [151–153] and cancer [154–156]. Given
their respective prevalence across the transcriptome,
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of the targeted RNA transcripts is at present unclear
[157]. It may be that these are distinct epitranscriptomic
processes that individually impact the fate of a given
RNA, or that there is a level of interaction that occurs
between these highly prevelant modifications. This will
be relevant to normal cell function but also in patho-
genic settings. As we understand more about the
biological functions of the distinct modifications and the
cell types that co-express the enzymes capable of writ-
ing, reading and erasing these marks, we will begin to
understand the cartography of RNA modifications and
how they reshape transcriptome output.
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